Background: In the US in 2021, invasive melanoma will account for an estimated 106,000
new cases and> 7,000 deaths. Somatic mutations that activate the MAPK signaling pathway …

Background: MAPK activating mutations are common in melanoma, with 40% of cases
attributed to oncogenic BRAF mutations and 20-25% NRAS mutations. Secondary MAPK …

The mitogen-activated protein kinase (MAPK) pathway is particularly important for the
survival and proliferation of melanoma cells. Somatic mutations in BRAF and NRAS are …

The RAF family kinases play critical roles in cancer progression. Recently, BRAF selective
inhibitors have shown significant clinical efficacy in melanoma patients bearing oncogenic …

Resistance to the RAF inhibitor vemurafenib arises commonly in melanomas driven by the
activated BRAF oncogene. Here, we report antitumor properties of RAF709, a novel ATP …

Although melanoma is the most aggressive skin cancer, recent advances in BRAF and/or
MEK inhibitors against BRAF-mutated melanoma have improved survival rates. Despite …

Abstract Mutations in KRas, NRas, BRaf and NF-1 that activate the Ras and mitogen-
activated protein kinase (MAPK) pathway are among the most common oncogenic drivers in …

TPS9597 Background: Over 70,000 patients are diagnosed with malignant melanoma in the
USA every year with a high proportion occurring in young people. Although treatments …

An activating somatic mutation in BRAF kinase (V600E) is found in approximately 70% of
melanomas, 50% of papillary thyroid cancers and 10% of colon cancers, fueling interest in …

Oncogenic activation of the BRAF serine/threonine kinase has been associated with
initiation and maintenance of melanoma tumors. As such, development of pharmacologic …